3Billion
Category: AI in Healthcare
South Korean AI-driven genetic diagnostics company using whole-genome/exome sequencing and AI variant interpretation to diagnose rare diseases, now expanding into newborn screening and drug discovery. 3Billion was founded in 2016. The company is led by Changwon Keum (금창원). Based in Seoul (Gangnam-gu), South Korea. Team size: 101-500. Total funding raised: $62M. Latest round: Post-IPO. Key investors include Wells Investment, JW (JW Medical), Korea Development Bank (KDB), Kiwoom Private Equity, Kiwoom Securities, GVA Asset Management.
- Founded
- 2016
- Headquarters
- Seoul (Gangnam-gu), South Korea
- Team size
- 101-500
- Total funding
- $62M
Value proposition
AI-powered genomic testing that diagnoses rare diseases faster and more accurately, with automated reanalysis and clinical review to raise diagnostic yield — expanding from rare-disease diagnosis into preventive newborn screening.
Products and solutions
3B-EXOME (boosted exome for rare disease diagnosis), 3B-GENOME (whole-genome sequencing incl. structural variants), 3B-VARIANT, 3B-INTERPRETER, GEBRA™ (AI variant prioritization), 3B-NEO (genomic newborn screening covering 704 clinically actionable genes/conditions), EVIDENCE 3Cnet reanalysis, drug discovery pipeline
Unique value
AI variant-prioritization platform (GEBRA) that boosts diagnostic yield via automated reanalysis, covering 7,000+ rare diseases in a single test, now extended to genomic newborn screening (3B-NEO, 704 actionable genes).
Target customer
Patients/families with suspected rare diseases, healthcare providers and diagnostic labs, hospitals (e.g. Seoul Asan Hospital), government health agencies (Korea Disease Control and Prevention Agency / KDCA), pharma partners
Industries served
Rare disease diagnostics, genomic newborn screening, preventive/precision medicine, drug discovery (rare disease drug pipeline)
Technology advantage
Proprietary AI variant interpretation and automated reanalysis (EVIDENCE 3Cnet) that raises diagnostic yield; CAP/CLIA-accredited lab; ISO/IEC 27001 certified; large-scale WGS data production experience from government projects (KDCA, National Bio Big Data).
How they differentiate
Combines AI-driven variant interpretation with unlimited automated reanalysis (updates as new disease-gene associations are discovered), a CAP/CLIA-accredited lab, and government-contract WGS experience — differentiating from standard exome labs by higher diagnostic yield and a newborn-screening expansion path.
Main competitors
Eone Diagnomics Genome Center, Macrogen (parent/spinoff partner), GeneDx (US), Illumina-connected rare disease diagnostics players
Key partnerships
AstraZeneca Korea (aHUS genetic diagnosis), Macrogen (diagnostic product development), Seoul Asan Hospital (K-gNBS newborn screening, 1,800 cases), Korea Disease Control and Prevention Agency / National Institute of Health (WGS newborn screening pilot), Global Genes & Roche (Xcelerate Rare challenge winner)
Notable customers
Seoul Asan Hospital (K-gNBS 1,800-case contract), Korea Disease Control and Prevention Agency (KDCA) government WGS projects, 790+ institutions across 70+ countries
Major milestones
2016 founded as Macrogen spinoff, 2018 Series A (₩30억), 2019 Series B (₩114억), 2021 Series C (₩140억, cumulative ~₩290억), 2022 Pre-IPO (₩131.5억), Nov 2024 KOSDAQ IPO (₩14.4B), 2025 participated in KDCA WGS newborn screening pilot, 2026 launched 3B-NEO genomic newborn screening (initially 595; panel now 704 genes), Apr 2026 raised ₩300억 post-IPO funding, Jun 2026 signed K-gNBS 1,800-case contract with Seoul Asan Hospital (KRW 900M), H1 2026 revenue up 56% to KRW 7.2B
Growth metrics
H1 2026 revenue KRW 7.2B (up 56% YoY); FY2025 revenue up 103% (3rd consecutive year of ~2x growth); trailing 12-month revenue ~$9.2M (as of Mar 2026); 70+ countries, 790+ institutions, 2,100+ healthcare providers
Market positioning
Publicly listed (KOSDAQ, ticker 394800.KQ) AI rare-disease diagnostics leader in Korea, expanding from diagnosis to preventive newborn screening and drug discovery; ~70+ countries, 790+ institutions, 2,100+ healthcare providers served.
Geographic focus
South Korea (home), expanding to US (Austin, Texas lab) and global markets post-IPO
Patents and IP
Proprietary AI variant-prioritization technology (GEBRA) and EVIDENCE 3Cnet reanalysis platform; CAP/CLIA-accredited and ISO/IEC 27001-certified operations
About Changwon Keum (금창원)
Ex-Macrogen Inc. (Team Leader); Geference Inc.; Bioinformatics and Molecular Design Research Center. Soongsil University bioinformatics (BS) and KAIST bioinformatics (MS). Founded 3billion in 2016 as a Macrogen spinoff.
Latest news about 3Billion
More AI in Healthcare companies
Official website: https://www.3billion.io